Beta
Back to PFE.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
revenue-chart

PFE Revenue

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

The latest data point for Pfizer's (PFE) revenue in Q4'25 stands at $17.56B USD, reflecting a modest year-over-year decline of -1.16% compared to the prior year, amid ongoing pressures in the pharmaceutical sector. Over the period from Q1'23 to Q4'25, revenue exhibited a volatile yet recovering trend, starting at a high of $18.28B in Q1'23 before dropping sharply to a low of $12.73B in Q2'23—a 30% decline—driven by post-pandemic market adjustments. From Q2'24 onward, the trajectory improved with consistent growth, peaking at $17.76B in Q4'24 and stabilizing around $16-17B in subsequent quarters, while YoY growth shifted from deep negatives (-54% in Q2'23) to positive territory (up to 33.8% in Q3'24) before moderating to slight declines in late 2025, indicating resilient operational recovery.